Suchergebnisse

For nearly thirty years, anthropologist and physician Paul Farmer has traveled to some of the most impoverished places on earth to bring comfort and the best possible medical care to the poorest of the poor. Driven by his stated intent to "make human rights substantial," Farmer has treated patients—and worked to address the root causes of their disease—in Haiti, Boston, Peru, Rwanda, and elsewhere in the developing world. In 1987, with several colleagues, he founded Partners In Health to provide a preferential option for the poor in health care. Throughout his career, Farmer has written eloquently and extensively on these efforts. Partner to the Poor collects his writings from 1988 to 2009 on anthropology, epidemiology, health care for the global poor, and international public health policy, providing a broad overview of his work. It illuminates the depth and impact of Farmer's contributions and demonstrates how, over time, this unassuming and dedicated doctor has fundamentally changed the way we think about health, international aid, and social justice.A portion of the proceeds from the sale of this book will be donated to Partners In Health

AbstractIntroductionLong‐term mortality among TB survivors appears to be higher than control populations without TB in many settings. However, data are limited among persons with HIV (PWH). We assessed the association between cured TB and long‐term mortality among persons with PWH in Haiti.MethodsA prospective cohort of PWH from the CIPRA HT‐001 trial was followed from study enrolment (August 2005 to July 2008) to study closure (December 2018) to compare mortality between participants with and without TB. The index date for the survival analysis was defined as 240 days after TB diagnosis or randomization date. Time to death was described using Kaplan–Meier curves, and log‐rank tests were used to compare time to death between the TB and no‐TB cohorts. The association between TB and long‐term mortality was estimated with multivariable Cox models.ResultsOf the 816 participants in the CIPRA HT‐001 trial, 77 were excluded for a history of TB prior to study enrolment and 31 were excluded due to death or attrition prior to the index date, leaving 574 in the no‐TB and 134 in the TB cohort. Twenty‐four (17.9%) participants in the TB and 48 (8.4%) in the no‐TB cohort died during follow‐up. Five and 10‐year mortality rates were 14.2% and 17.9% respectively, in the TB cohort, and 6.1% and 8.4% in the no‐TB cohort. In Kaplan–Meier analysis, participants in the TB cohort had a significantly shorter time to death (log‐rank p < 0.001). In multivariable analysis, TB treatment was the only predictor of mortality (HR: 2.78; 95% CI: 1.61, 4.79). Sensitivity analyses, which included only baseline TB cases, an index date of two years after TB diagnosis, and study enrolment and case‐control matching yielded results that were consistent with primary analyses.ConclusionsPWH who are successfully treated for TB have higher long‐term mortality than those who are never diagnosed with TB, even after accounting for acute TB‐related mortality. A better understanding of the underlying mechanisms associated with TB sequelae is critically needed to guide specific interventions. Until then, more aggressive measures for health promotion and disease prevention are essential to improve long‐term survival for PWH after TB treatment.